<DOC>
	<DOCNO>NCT01065012</DOCNO>
	<brief_summary>Open-Label Phase 3 study evaluate long-term safety efficacy udenafil , orally administer selective inhibitor PDE-5 treatment subject erectile dysfunction ( ED ) .</brief_summary>
	<brief_title>Treatment Erectile Dysfunction - Long Term Safety Efficacy</brief_title>
	<detailed_description>Patients complete double-blind phase enter Study 01409 intermediate dose . Up dose adjustment allow .</detailed_description>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Udenafil</mesh_term>
	<criteria>Subject complete Study PR01209 PR01309 Continues stable monogamous relationship consent female partner least 19 year age . Partner pregnant lactating Symptomatic coronary artery disease , myocardial infarction cardiac surgical procedure . Cardiac arrhythmia require antiarrhythmic treatment Symptomatic congestive heart failure Taking nitrate medication form Uncontrolled diabetes ( HbA1c â‰¥ 13 % ) Hypersensitivity phosphodiesterase type 5 ( PDE5 ) inhibitor</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>